Anti-Cancer drug NSC-631570 (Ukrain): Induction of the apoptosis in cancer cells
International Conference on Pathology and Surgical Pathology
September 06-07, 2018 | Edinburgh, Scotland
Ukrainian Anti-Cancer Institute, Austria
Scientific Tracks Abstracts : J Pathol Dis Biol
In the study on the erythroleucemia cells KÃ¢ÂÂ562, it was revealed NSCÃ¢ÂÂ631570 to bring about the bimodal death of cancer cells. At lower concentrations of NSCÃ¢ÂÂ631570, cancer cells die in as a consequence of apoptosis. At higher concentrations, the formation of microtubules is inhibited and polyploidy occurs. In the tests on human cervix carcinoma cells HeLa, squamous carcinoma cells WHCO5, normal kidney cell line Graham 293, and transformed kidney cell line Vero from African green monkey the researchers of the University of Pretoria, South Africa revealed NSCÃ¢ÂÂ631570 Ã¢ÂÂis selectively toxic to malignant cells by causing a metaphase block which is characterised by abnormal chromosomal distribution, and results in the formation of micronuclei and in apoptosis. The scientists of the Eberhard Karl University (TuÃÂbingen, Germany) investigated the effect of NSCÃ¢ÂÂ631570 on the cell survival, the cell cycle modification and the apoptosis induction alone and combined with radiation (IR). They discovered NSCÃ¢ÂÂ631570 combined with IR increased the toxicity against the cell lines CCLÃ¢ÂÂ221 and UÃ¢ÂÂ138MG. The normal human skin and lung fibroblasts were protected from the damaging effects of IR. Estimating the cell proliferation according to the BrdU uptake in the cell lines AsPC1, BxPC3, MiaPaCa2, Jurkat, and THPÃ¢ÂÂ1 and the cell cycle phases by means of Giemsa staining, the authors established NSCÃ¢ÂÂ631570 at a dose of 10 ÃÂ¼g/ml brought about a considerable accumulation of cancer cells in the G2/M phase after 24 h incubation. The apoptosis rate in the peripheral mononuclears was similar at the same incubation conditions. Moreover, the mitogene stimulated lymphocytes showed increased blastogen reaction. Effect of NSCÃ¢ÂÂ631570 on cell survival and apoptosis in the androgenÃ¢ÂÂindependent prostate cancer cell line PCÃ¢ÂÂ3 was studied. Cell viability was assessed using the dimethyl thiazolyl tetrazolium bromide (MTT) method in PCÃ¢ÂÂ3 cells after treatment with Ukrain. The IC50 value was observed in 10 ÃÂ¼g concentration of Ukrain. Bax, Bad, and FasL mRNA expression was analyzed by reverse transcriptaseÃ¢ÂÂpolymerase chain reaction, and protein expressions of pÃ¢ÂÂAkt, BclÃ¢ÂÂ2, and caspase 10 were determined by westernÃ¢ÂÂblot analysis. Nuclei were stained with 4Ã¢ÂÂ,6Ã¢ÂÂdiamidinoÃ¢ÂÂ2Ã¢ÂÂ phenylindole, dihydrochloride (DAPI). NSCÃ¢ÂÂ631570 significantly increased the proÃ¢ÂÂapoptotic mRNA expression of Bad, Bax, and FasL; decreased the cell survival protein pÃ¢ÂÂAkt and the antiÃ¢ÂÂapoptotic protein BclÃ¢ÂÂ2; and increased the protein levels of cleaved poly(ADP)Ã¢ÂÂribose polymerase (PARP) and caspaseÃ¢ÂÂ10. The results of this study suggest that NSCÃ¢ÂÂ631570 decreases the cell survival of androgenÃ¢ÂÂindependent prostate cancer cells.
Wassil Nowicky, Director of “Nowicky Pharma” and President of the Ukrainian Anti- Cancer Institute (Vienna, Austria). Has finished his study at the Radiotechnical faculty of the technical University of Lviv (Ukraine) with the end of 1955 with graduation to “Diplomingeniueur” in 1960 which title was nostrificated in Austria in 1975. Inventor of the anticancer preparation on basis of celandine alkaloids “NSC-631570”. Author of over 300 scientific articles dedicated to cancer research. Dr. Wassil Nowicky is a real member of the New York Academy of Sciences, member of the European Union for Applied Immunology and of the American Association for scientific progress, honorary doctor of the Janka Kupala University in Hrodno, doctor “honoris causa” of the Open international university on complex medicine in Colombo, honorary member of the Austrian Society of a name od Albert Schweizer. He has received the award for merits of National guild of pharmacists of America. the award of Austrian Society of sanitary, hygiene and public health services and others.
E-mail: [email protected]